B. V. Van Eyll

Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.

M. Espié, J. Baselga, P. Hoff, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of paclitaxel carried in lipid core nanoparticles in patients with late-stage solid cancers with bone metastases: Lack of toxicity and therapeutic benefits

F. Freitas, S. Graziani, B. V. Van Eyll, 2022, Journal of bone oncology.

Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).

Ying Cheng, Tae Won Kim, T. Pintér, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of quality of life in patients with metastatic colorectal cancer treated with capecitabine.

F. Franke, J. Segalla, B. V. Van Eyll, 2008, Clinical colorectal cancer.

Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial.

C. Barrios, P. Hoff, V. Passos, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Signal transduction of the GLP‐1‐receptor cloned from a human insulinoma

B. Göke, H. Bode, B. V. Van Eyll, 1994, FEBS letters.

Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma

R. Maranhão, S. Graziani, B. V. Van Eyll, 2017, Medical Oncology.

Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial.

C. Barrios, P. Hoff, V. Passos, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.